Akker-van Marle, M.E. van den

screening cancer policy screening policies effect examination incidence cost-effectiveness screening program health smear program stage netherland country interval number screening policy ratio analysis disease cancer screening women value life-year level cost-effectiveness ratio population estimate price level pap smears screening interval result cancer institute price range 3 years life expectancy treatment background incidence health effects difference model screening costs miscan sensitivity preinvasive woman journal age range screening test cost-effectiveness ratios dutch background situation attendance table van oortmarssen gj baseline study analyses future costs dollar expectancy costeffectivenes mortality screening examinations erasmus university rotterdam van ballegooijen m institute microsimulation screening analysis comparison february cost-effectiveness analysis lifetime article frontier ballegooijen discounting australia